Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
Authors
Mudgal Kothekar
Jerry Bagel (ORCID: https://orcid.org/0000-0001-5241-0915)
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
Mudgal Kothekar, Jerry Bagel, Iris Kopeloff, Lynda Spelman et al.
Citations
2 citations
Journal
Journal of the American Academy of Dermatology
Topics
Autoimmune Bullous Skin Diseases
Field-Weighted Citation Impact (FWCI)
0.85
article
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial
Mudgal Kothekar, Jerry Bagel, Iris Kopeloff, Lynda Spelman, Paul S. Yamauchi, Siu‐Long Yao, Kurt Gebauer, Howard Sofen, Ranga Gogineni, Tushar Nishandar, Michael Crane
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of the American Academy of DermatologyVol. 92(4)
Institutions
University of California, Los Angeles (US), UCLA Health (US), Fremantle Hospital (AU), VA New Jersey Health Care System (US), Probity Medical Research (CA), Sun Pharma (United States) (US), Sun Pharma (India) (IN), Sun Pharma Advanced Research (India) (IN), Veracity Clinical Research (AU), Sun Chemical (United States) (US)